Alpelisib(Piqray)

Alpelisib is an oral phosphatidylinositol-3-kinase (PI3K) inhibitor. Its mechanism of action is to block the activity of PI3K enzymes, inhibit the proliferation and spread of tumor cells, and simultaneously induce the apoptosis of breast cancer cells.

50mg*28tablets
150mg*28tablets

WhatsApp

To ensure medication safety, consult customer service for free before purchasing. Returns/exchanges are not accepted except for quality issues.

Authentic

Guarantee

Fast Delivery

Privacy

Alpelisib Drug News

First PIK3CA-Mutated HR+/HER2- Breast Cancer Therapy Piqray (Alpelisib) Significantly Prolongs Overa

Novartis announced the final overall survival (OS) analysis results from the phase III SOLAR‑1 study of Piqray (alpelisib), a novel breast cancer ther···【Read More】
Update: 02 Mar,2026Source: Haiou HealthViews: 70
Breast Cancer New Drug Piqray for PIK3CA-Mutated HR+/HER2- Breast Cancer: Significantly Extends Surv

Novartis recently announced the final overall survival (OS) analysis results of the phase III SOLAR-1 study of the new breast cancer drug Piqray (alpe···【Read More】
Update: 02 Mar,2026Source: Haiou HealthViews: 71
Novartis PI3K Inhibitor Piqray Approved in the EU: First Therapy for PIK3CA-Mutated HR+/HER2- Breast

EU Approval Details of PiqrayNovartis recently announced that the European Commission (EC) has approved Piqray (alpelisib) in combination with fulvest···【Read More】
Update: 02 Mar,2026Source: Haiou HealthViews: 73